Association of anticoagulant use with clinical outcomes from crizotinib in ALK ‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001

BACKGROUND: ROS1‐ and ALK‐rearranged advanced NSCLCs are associated with increased thromboembolic risk. We hypothesized that a prothrombotic phenotype offers an evolutionary advantage to subsets of these cancers. The impact of this phenotype could alter outcomes from targeted therapy. METHODS: In a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Terry L., Tsui, David C. C., Wang, Sherry, Usari, Tiziana, Patil, Tejas, Wilner, Keith, Camidge, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741966/
https://www.ncbi.nlm.nih.gov/pubmed/35510711
http://dx.doi.org/10.1002/cam4.4789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741966/
https://www.ncbi.nlm.nih.gov/pubmed/35510711
http://dx.doi.org/10.1002/cam4.4789

Ejemplares similares